European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should not be approved, once again diverging from their U.S. counterparts. The Committee for ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Eli Lilly’s global CEO David Ricks has highlighted the significant costs of bringing new drugs to market, revealing that the average cost of developing a single drug is around $4 billion—even before ...

He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market ...

LAOAG CITY — The Commission on Elections (Comelec) 1 (Ilocos Norte) gave local candidates three days to take down their oversized and illegally placed campaign posters across the province. The poll ...

Eli Lilly is gearing up for a breakthrough in diabetes and obesity treatment with its upcoming oral GLP-1 drug, orforglipron. In an exclusive conversation with CNBC-TV18’s Shereen Bhan, the company’s ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...